Minimization of immunosuppression in adult liver transplantation: New strategies and tools

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 685-690

  Londoño, Maria Carlota ^a   López, Marta Cecilia ^a   Sánchez Fueyo, Alberto ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

adult liver transplantation; biomarkers; immunosuppression; tolerance

Indexed keywords

ALEMTUZUMAB; BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; RAPAMYCIN; THYMOCYTE ANTIBODY;

ALLOGRAFT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER PARENCHYMA; LIVER TRANSPLANTATION; MONOTHERAPY; NONHUMAN; ORGAN DONOR; REGULATORY T LYMPHOCYTE; REVIEW;

ADULT; BIOLOGICAL MARKERS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; TRANSPLANTATION TOLERANCE; WITHHOLDING TREATMENT;

EID: 78649648091     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283402c55     Document Type: Review

References (46)

1. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352:1371-1373.
2. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immuno-therapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939.
3. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer pro-gression by a cell-autonomous mechanism. Nature 1999; 397:530-534.
4. Penn I. Tumors arising in organ transplant recipients. Adv Cancer Res 1978; 28:31-61.
5. Romagnoli J, Citterio F, Violi P, et al. Posttransplantdiabetes mellitus: acase-control analysis of the risk factors. Transpl Int 2005; 18:309-312.
6. Fletcher JT, Nankivell BJ, Alexander SI. Chronic allograft nephropathy. Pediatr Nephrol 2009; 24:1465-1471.
7. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490-500.
8. Rush D. Protocol biopsies for renal transplantation. Saudi J Kidney Dis Transpl 2010; 21:1-9.
9. Yu YY, Ji J, Zhou GW, et al. Liver biopsy in evaluation of complications following liver transplantation. World J Gastroenterol 2004; 10:1678-1681.
10. Sumitran-Holgersson S, Ge X, Karrar A, et al. A novel mechanism of liver allograft rejection facilitated by antibodies to liver sinusoidal endothelial cells. Hepatology 2004; 40:1211-1221.
11. Ge X, Nowak G, Ericzon BG, Sumitran-Holgersson S. Liver sinusoidal endothelial cell function in rejected and spontaneously accepted rat liver allografts. Transpl Int 2008; 21:49-56.
12. Chen Y, Liu Z, Liang S, et al. Role of Kupffercells in the induction oftolerance oforthotopic livertransplantation in rats. Liver Transpl 2008; 14:823-836.
13. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplanttolerance. Transplantation 2008; 85:369-377.
14. Toyokawa H, Nakao A, Bailey RJ, et al. Relative contribution of direct and indirect allorecognition in developing tolerance after livertransplantation. Liver Transpl 2008; 14:346-357.
15. Kurtz J, Wekerle T, Sykes M. Tolerance in mixed chimerism: a role for regulatory cells? Trends Immunol 2004; 25:518-523.
16. Demirkiran A, Bosma BM, Kok A, et al. Allosuppressive donor CD4+CD25+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007; 178:6066-6072.
17. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74:1405-1409.
18. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-361.
19. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006; 12:1523-1528.
20. Donckier V, Craciun L, Lucidi V, et al. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells. Transplantation 2009; 87 (Suppl 9):S91-S95.
21. Calne R, Friend P, Moffatt S, et al. Propetolerance, perioperativecampath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702.
22. Starzl TE, Murase N, Abu-Elmagd K, et al.Tolerogenicimmunosuppressionfor organ transplantation. Lancet 2003; 361:1502-1710.
23. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitisCvirus.Transplantation 2004; 78:966-991.
24. De Ruvo N, Cucchetti A, Lauro A, et al. Preliminary results of a 'prope' tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in livertransplantation. Transplantation 2005; 80:8-12. (Pubitemid 40980888)
25. Benitez C. ATG-Fresenius treatment and low dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant (in press).
26. Starzl TE. Cell migration and chimerism: a unifying concept in transplantation-with particular reference to HLA matching and tolerance induction. Trans-plant Proc 1993; 25:8-12.
27. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in livertransplant recipients. Transplantation 1997; 63:243-249.
28. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosup-pression withdrawal after liver transplantation. Hepatology 1998; 27:926-933.
29. Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppres-sion withdrawal after liver transplantation. Transplant Proc 2005; 37:1708-1709. (Pubitemid 40790804)
30. Takatsuki M, Uemoto S, Inomata Y, et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol 2001; 8:279-286.
31. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk? Transplanta-tion 2005; 79:1157-1159.
32. Tryphonopoulos P, Tzakis AG, Weppler D, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotrans-plantation. Am J Transplant 2005; 5:608-613.
33. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immuno-suppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44:702-709.
34. Assy N, Adams PC, Myers P, et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of urso-deoxycholic acid. Transplantation 2007; 83:1571-1576. (Pubitemid 46987908)
35. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86: 1370-1378.
36. Feng S, Ekong U, Lobritto S. ITN029ST: Immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study. Am J Transplant 2009; 9(S2):abstract 189.
37. Benitez C, Lozano JJ, Mart́inez-Llordella M. Use of transcriptional biomar-kers to identify liver transplant recipients who can successfully discontinue immunosuppressive therapy. Am J Transplant 2010; 10(S4):abstract 517.
38. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780.
39. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsyinterpretationforcauses of late liver allograft dysfunction. Hepatology 2006; 44:489-501.
40. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120-141.
41. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation.Transplantation 2009; 87:606-614.
42. Castellaneta A, Thomson AW, Nayyar N, et al. Monitoring the operationally tolerantliverallograft recipient. Curr Opin Organ Transplant 2010; 15:28-34.
43. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.
44. Mart́inez-Llordella M, Lozano JJ, Puig-Pey I, et al. Usingtranscriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
45. Kawasaki M, Iwasaki M, Koshiba T, et al. Gene expression profile analysis of the peripheral blood mononuclear cells from tolerant living-donor liver trans-plant recipients. Int Surg 2007; 92:276-286.
46. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86:1837-1843.